Skip to main content
ALTERITY THERAPEUTICS LIMITED logo

ALTERITY THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · ATH ISIN · AU0000043945 LEI · 52990045JUZVZ9QL3159 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,319 across all filing types
Latest filing 2026-05-18 Regulatory Filings
Country AU Australia
Listing ASX ATH

About ALTERITY THERAPEUTICS LIMITED

https://alteritytx.com/

Alterity Therapeutics Limited is a clinical-stage company focused on developing disease-modifying therapies for neurodegenerative disorders. The company's research and development efforts center on addressing the underlying pathology of conditions such as Multiple System Atrophy (MSA) and Parkinson's disease. Its lead therapeutic candidate, ATH434, is an orally administered small molecule designed to redistribute excess iron in the brain, thereby inhibiting the aggregation of alpha-synuclein and reducing oxidative stress. By targeting these specific mechanisms, the company aims to preserve neuronal integrity and slow the progression of parkinsonian diseases. Alterity utilizes a specialized platform to identify compounds that modulate metal-protein interactions, focusing on first-in-class treatments for orphan diseases with high unmet medical needs.

Recent filings

Filing Released Lang Actions
Alterity Data Supports ATH434 Phase 3 Advancement in MSA 6 pages 275.7KB
Regulatory Filings Classification · 85% confidence The document is a press release announcing clinical data presentations at medical conferences and plans for Phase 3 development. It does not contain financial statements, management discussion of results, a proxy solicitation, earnings highlights, or a detailed investor slide deck. It is a general corporate announcement with forward-looking statements, serving as a catch-all press release rather than a specific regulatory filing or report. Therefore, it falls under the fallback category for miscellaneous regulatory announcements.
2026-05-18 English
Corporate Presentation May 2026 46 pages 3.4MB
Investor Presentation Classification · 93% confidence The document is a slide deck titled “Corporate Presentation” by Alterity Therapeutics, containing forward‐looking statements, strategic overview, clinical program details, efficacy data, development pipeline, and trial results. It is clearly an investor‐oriented presentation rather than a regulatory filing, earnings release, or full financial report. Therefore, it matches the definition of an Investor Presentation (IP).
2026-05-11 English
Alterity Announces Publication on MRI as Biomarker for MSA 5 pages 251.3KB
Regulatory Filings Classification · 38% confidence The document is a corporate press release announcing the publication of a peer‐reviewed scientific study in NeuroImage. It contains no financial results, no management or board changes, no regulatory filing or offering details, and no report itself—it simply announces a publication. It does not fit specific categories like earnings release, annual/interim report, proxy, M&A, etc. Therefore it falls into the fallback “Regulatory Filings” category (RNS) for miscellaneous corporate announcements.
2026-05-10 English
Alterity to Deliver Presentations at May Medical Meetings 3 pages 215.6KB
Regulatory Filings
2026-05-06 English
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 449.2KB
Regulatory Filings
2026-04-29 English
Consolidation/Split - ATH 10 pages 33.1KB
Regulatory Filings
2026-04-29 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.